Citigroup Portfolio holdings
Citigroup Inc., formed in 1998 through the landmark merger of Citicorp and Travelers Group, with roots tracing back to the 1812 founding of City Bank of New York, is a global financial powerhouse headquartered in New York City, managing trillions in assets. Operating in over 160 countries, Citigroup offers a broad spectrum of services, including consumer banking (via Citibank), investment banking, wealth management, and trading, serving millions of retail customers and major corporations, governments, and institutions worldwide. Under CEO Jane Fraser since 2021—the first woman to lead a major U.S. bank—Citigroup has focused on streamlining operations, exiting consumer banking in 13 markets to bolster its institutional and wealth management focus, while navigating post-2008 regulatory scrutiny and fines. Known for its vast global footprint and resilience through crises, Citigroup remains a key player in international finance, blending retail accessibility with high-stakes capital markets expertise.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$2.05B |
| 2 |
Invesco QQQ Trust
QQQ
|
+$404M |
| 3 |
AstraZeneca
AZN
|
+$342M |
| 4 |
Vanguard S&P 500 ETF
VOO
|
+$288M |
| 5 |
Willis Towers Watson
WTW
|
+$227M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Icahn Enterprises
IEP
|
+$641M |
| 2 |
Microsoft
MSFT
|
+$549M |
| 3 |
State Street SPDR S&P Oil & Gas Exploration & Production ETF
XOP
|
+$538M |
| 4 |
Alphabet (Google) Class A
GOOGL
|
+$294M |
| 5 |
SCHW
Charles Schwab
SCHW
|
+$275M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 12.22% |
| 2 | Financials | 7.52% |
| 3 | Healthcare | 6.46% |
| 4 | Consumer Discretionary | 6.41% |
| 5 | Communication Services | 4.56% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1801
CALL
Bunge Global
BG
$21.1B
| $5.52M | ﹤0.01% |
70,600
| – | – |
|
|
SRNE
1802
DELISTED
Sorrento Therapeutics, Inc.
SRNE
| $5.52M | ﹤0.01% |
569,380
+86,314
| +18% | +$687K |
|
1803
Essential Properties Realty Trust
EPRT
$6.97B
| $5.51M | ﹤0.01% |
203,683
+67,094
| +49% | +$1.74M |
|
|
BPMC
1804
DELISTED
Blueprint Medicines
BPMC
| $5.49M | ﹤0.01% |
62,398
+18,064
| +41% | +$1.66M |
|
1805
MannKind Corp
MNKD
$1.2B
| $5.49M | ﹤0.01% |
1,006,888
-37,342
| -4% | -$162K |
|
1806
Invesco Variable Rate Preferred ETF
VRP
$2.98B
| $5.48M | ﹤0.01% |
208,219
+5,752
| +3% | +$150K |
|
1807
Travel + Leisure Co
TNL
$4.74B
| $5.47M | ﹤0.01% |
92,083
-24,414
| -21% | -$1.55M |
|
1808
Amdocs
DOX
$6.02B
| $5.46M | ﹤0.01% |
70,588
-155,033
| -69% | -$12M |
|
|
WWE
1809
DELISTED
World Wrestling Entertainment
WWE
| $5.45M | ﹤0.01% |
94,116
+11,487
| +14% | +$653K |
|
1810
Macerich
MAC
$7.46B
| $5.45M | ﹤0.01% |
298,380
-10,722
| -3% | -$161K |
|
1811
iShares MSCI Australia ETF
EWA
$1.38B
| $5.43M | ﹤0.01% |
209,147
+33,340
| +19% | +$878K |
|
1812
CALL
Liberty Global Class A
LBTYA
$3.55B
| $5.43M | ﹤0.01% |
+200,000
| New | +$5.4M |
|
1813
Cogent Communications
CCOI
$600M
| $5.43M | ﹤0.01% |
70,602
+18,459
| +35% | +$1.37M |
|
|
CLDL
1814
DELISTED
Direxion Daily Cloud Computing Bull 2X Shares
CLDL
| $5.42M | ﹤0.01% |
200,000
| – | – |
|
1815
Flex
FLEX
$37.8B
| $5.4M | ﹤0.01% |
400,844
+256,650
| +178% | +$3.49M |
|
1816
Global X Emerging Markets Bond ETF
EMBD
$249M
| $5.39M | ﹤0.01% |
200,000
| – | – |
|
|
1817
PUT
AstraZeneca
AZN
$271B
| $5.39M | ﹤0.01% |
+45,000
| New | +$4.94M |
|
1818
CRISPR Therapeutics
CRSP
$4.63B
| $5.37M | ﹤0.01% |
33,161
+7,135
| +27% | +$868K |
|
1819
BlackBerry
BB
$4.6B
| $5.37M | ﹤0.01% |
438,496
+50,606
| +13% | +$530K |
|
|
SGMO
1820
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
| $5.37M | ﹤0.01% |
448,152
+11,878
| +3% | +$134K |
|
1821
Fate Therapeutics
FATE
$267M
| $5.36M | ﹤0.01% |
61,750
+6,085
| +11% | +$490K |
|
|
BLDP
1822
Ballard Power Systems
BLDP
$772M
| $5.34M | ﹤0.01% |
293,969
+139,177
| +90% | +$2.59M |
|
1823
CACI
CACI
$10.9B
| $5.33M | ﹤0.01% |
20,887
-1,173
| -5% | -$303K |
|
1824
CALL
Centene
CNC
$31.3B
| $5.32M | ﹤0.01% |
+73,000
| New | +$5M |
|
|
DRNA
1825
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
| $5.29M | ﹤0.01% |
141,868
-25,471
| -15% | -$781K |
|
Similar funds
Citigroup's Q2 2021 Portfolio in Review
As of Q2 2021, Citigroup held 6,654 positions worth $166B, up 7.5% from $155B the previous quarter. Its ten largest holdings account for 20% of the portfolio.
Citigroup's Q2 2021 filing shows 397 new, 2,681 increased, 2,205 reduced and 444 closed positions. Its largest new stake was Elliott Opportunity II Corp. Units, each consisting of one Class A ordinary share and one-fourth of one redeemable warrant: 7,128,000 shares worth $71.4M. The largest sale was Icahn Enterprises, an estimated $641M.
By sector, the portfolio is most concentrated in Technology at 12% of assets, down from 12% a quarter earlier, followed by Financials and Healthcare.
- Citigroup's largest Q2 2021 buy was Elliott Opportunity II Corp. Units, each consisting of one Class A ordinary share and one-fourth of one redeemable warrant: 7,128,000 shares worth $71.4M.
- Citigroup added most to State Street SPDR S&P 500 ETF Trust in Q2 2021, an estimated $2.05B increase.
- Citigroup's biggest Q2 2021 reduction was Icahn Enterprises, cutting an estimated $641M.
- Citigroup fully exited RealPage, Inc. in Q2 2021, selling an estimated $226M.
- Citigroup's ten largest holdings make up 20% of its $166B portfolio in Q2 2021.
- Citigroup opened 397 new positions and closed 444 in Q2 2021.
- Citigroup's portfolio value rose 7.5% quarter-over-quarter to $166B.
Based on Citigroup's 13F filing for Q2 2021, filed 10 Aug 2021.